HRP20221516T1 - Derivati naftiridinona i njihova uporaba u liječenju aritmije - Google Patents
Derivati naftiridinona i njihova uporaba u liječenju aritmije Download PDFInfo
- Publication number
- HRP20221516T1 HRP20221516T1 HRP20221516TT HRP20221516T HRP20221516T1 HR P20221516 T1 HRP20221516 T1 HR P20221516T1 HR P20221516T T HRP20221516T T HR P20221516TT HR P20221516 T HRP20221516 T HR P20221516T HR P20221516 T1 HRP20221516 T1 HR P20221516T1
- Authority
- HR
- Croatia
- Prior art keywords
- chloro
- naphthyridin
- dichlorophenyl
- methyl
- hydroxymethyl
- Prior art date
Links
- 206010003119 arrhythmia Diseases 0.000 title claims 2
- 230000006793 arrhythmia Effects 0.000 title 1
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical class C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- 150000003839 salts Chemical class 0.000 claims 13
- 239000003112 inhibitor Substances 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 125000001424 substituent group Chemical group 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 239000003416 antiarrhythmic agent Substances 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- -1 -CH2CN Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 3
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 2
- DDDSGZFENQKDDY-JTQLQIEISA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[(2S)-2,3-dihydroxypropoxy]-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OC[C@H](CO)O DDDSGZFENQKDDY-JTQLQIEISA-N 0.000 claims 2
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 2
- 108010061846 Cholesterol Ester Transfer Proteins Proteins 0.000 claims 2
- 102000012336 Cholesterol Ester Transfer Proteins Human genes 0.000 claims 2
- 102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 claims 2
- 108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 claims 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims 2
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 claims 2
- 101500016415 Lophius americanus Glucagon-like peptide 1 Proteins 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 102000000536 PPAR gamma Human genes 0.000 claims 2
- 108010016731 PPAR gamma Proteins 0.000 claims 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 229940124308 alpha-adrenoreceptor antagonist Drugs 0.000 claims 2
- 239000002876 beta blocker Substances 0.000 claims 2
- 229940097320 beta blocking agent Drugs 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- 229930003827 cannabinoid Natural products 0.000 claims 2
- 239000003557 cannabinoid Substances 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 238000000634 powder X-ray diffraction Methods 0.000 claims 2
- 239000002464 receptor antagonist Substances 0.000 claims 2
- 229940044551 receptor antagonist Drugs 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- 239000003868 thrombin inhibitor Substances 0.000 claims 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 1
- LFOZKAQFOKTGII-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-2-methyl-7-(methylamino)-1,6-naphthyridin-4-one Chemical compound ClC1=C(C(=CC=C1)Cl)N1C(=CC(C2=C(N=C(C=C12)NC)OCC(CO)O)=O)C LFOZKAQFOKTGII-UHFFFAOYSA-N 0.000 claims 1
- QHACNFMTZPBWRL-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-7-ethyl-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC1=C(C(=CC=C1)Cl)N1C(=CC(C2=C(N=C(C=C12)CC)OCC(CO)O)=O)C QHACNFMTZPBWRL-UHFFFAOYSA-N 0.000 claims 1
- OEYIWLUJHKVFFP-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-7-methoxy-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC1=C(C(=CC=C1)Cl)N1C(=CC(C2=C(N=C(C=C12)OC)OCC(CO)O)=O)C OEYIWLUJHKVFFP-UHFFFAOYSA-N 0.000 claims 1
- PMNIPBGSJIEKQS-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-8-ethyl-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC1=C(C(=CC=C1)Cl)N1C(=CC(C2=C(N=CC(=C12)CC)OCC(CO)O)=O)C PMNIPBGSJIEKQS-UHFFFAOYSA-N 0.000 claims 1
- LQMKJBAFJXVTEA-UHFFFAOYSA-N 1-(2-chloro-6-ethylphenyl)-5-(2,3-dihydroxypropoxy)-7-ethyl-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC1=C(C(=CC=C1)CC)N1C(=CC(C2=C(N=C(C=C12)CC)OCC(CO)O)=O)C LQMKJBAFJXVTEA-UHFFFAOYSA-N 0.000 claims 1
- JDMFEDXJXXQMKN-UHFFFAOYSA-N 1-[4-(3-amino-3-methylbut-1-ynyl)-2,6-dichlorophenyl]-8-chloro-5-(2,3-dihydroxypropoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound NC(C#CC1=CC(=C(C(=C1)Cl)N1C(=CC(C2=C(N=CC(=C12)Cl)OCC(CO)O)=O)C)Cl)(C)C JDMFEDXJXXQMKN-UHFFFAOYSA-N 0.000 claims 1
- JEIFFJHSPMANBT-UHFFFAOYSA-N 3,5-dichloro-4-[2-methyl-4-oxo-5-(1H-pyrazol-5-yl)-1,7-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(C=NC=C12)C1=NNC=C1)=O)C)Cl JEIFFJHSPMANBT-UHFFFAOYSA-N 0.000 claims 1
- IOJQHMDFIWJXLF-UHFFFAOYSA-N 3,5-dichloro-4-[2-methyl-5-(1-methylpyrazol-4-yl)-4-oxo-1,7-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(C=NC=C12)C=1C=NN(C=1)C)=O)C)Cl IOJQHMDFIWJXLF-UHFFFAOYSA-N 0.000 claims 1
- OVOYJHPFWJNUQB-UHFFFAOYSA-N 3,5-dichloro-4-[5-(2-hydroxyethylamino)-2-methyl-4-oxo-1,7-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(C=NC=C12)NCCO)=O)C)Cl OVOYJHPFWJNUQB-UHFFFAOYSA-N 0.000 claims 1
- YHMZEOXOMITJAP-UHFFFAOYSA-N 3,5-dichloro-4-[5-(3-hydroxyazetidin-1-yl)-2-methyl-4-oxo-1,7-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(C=NC=C12)N1CC(C1)O)=O)C)Cl YHMZEOXOMITJAP-UHFFFAOYSA-N 0.000 claims 1
- FJJRZFWOCQMGEY-UHFFFAOYSA-N 3,5-dichloro-4-[5-[2-(1H-imidazol-5-yl)ethylamino]-2-methyl-4-oxo-1,7-naphthyridin-1-yl]benzonitrile Chemical compound N1C=NC(=C1)CCNC1=C2C(C=C(N(C2=CN=C1)C1=C(C=C(C#N)C=C1Cl)Cl)C)=O FJJRZFWOCQMGEY-UHFFFAOYSA-N 0.000 claims 1
- JTBFLNMQUBKHLQ-UHFFFAOYSA-N 3,5-dichloro-4-[8-chloro-5-(2,3-dihydroxypropoxy)-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound CC1=CC(=O)C2=C(OCC(O)CO)N=CC(Cl)=C2N1C1=C(Cl)C=C(C=C1Cl)C#N JTBFLNMQUBKHLQ-UHFFFAOYSA-N 0.000 claims 1
- XTTWQOXKGSVQSX-UHFFFAOYSA-N 3,5-dichloro-4-[8-chloro-5-(2-hydroxyethoxyamino)-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(N=CC(=C12)Cl)NOCCO)=O)C)Cl XTTWQOXKGSVQSX-UHFFFAOYSA-N 0.000 claims 1
- NCMYMRCUTWGGJO-UHFFFAOYSA-N 3,5-dichloro-4-[8-chloro-5-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(N=CC(=C12)Cl)N1CCN(CC1)CCO)=O)C)Cl NCMYMRCUTWGGJO-UHFFFAOYSA-N 0.000 claims 1
- XNEUDCWKNMCPIY-GDBMZVCRSA-N 3,5-dichloro-4-[8-chloro-5-[[(3R,4S)-4-hydroxyoxolan-3-yl]amino]-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C=C(C#N)C=C(C=1N1C(=CC(C2=C(N=CC(=C12)Cl)N[C@@H]1COC[C@H]1O)=O)C)Cl XNEUDCWKNMCPIY-GDBMZVCRSA-N 0.000 claims 1
- QTLNAOKNMRRSKL-UHFFFAOYSA-N 3-[[8-chloro-1-(2,6-dichlorophenyl)-2-methyl-4-oxo-1,6-naphthyridin-5-yl]amino]-2-hydroxy-N-(2-hydroxyethyl)propanamide Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)NCC(C(=O)NCCO)O QTLNAOKNMRRSKL-UHFFFAOYSA-N 0.000 claims 1
- DCKMLYPIFNABIX-UHFFFAOYSA-N 3-chloro-2-[8-chloro-2-cyclopropyl-5-(2,3-dihydroxypropoxy)-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C(=C(C#N)C=CC=1)N1C(=CC(C2=C(N=CC(=C12)Cl)OCC(CO)O)=O)C1CC1 DCKMLYPIFNABIX-UHFFFAOYSA-N 0.000 claims 1
- YFKJAUKINKKAPS-UHFFFAOYSA-N 3-chloro-2-[8-chloro-5-(2,3-dihydroxypropoxy)-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C(=C(C#N)C=CC=1)N1C(=CC(C2=C(N=CC(=C12)Cl)OCC(CO)O)=O)C YFKJAUKINKKAPS-UHFFFAOYSA-N 0.000 claims 1
- RTXJBTFTKDIJGJ-UHFFFAOYSA-N 3-chloro-2-[8-chloro-5-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]-2-methyl-4-oxo-1,6-naphthyridin-1-yl]-5-fluorobenzonitrile Chemical compound ClC=1C(=C(C#N)C=C(C=1)F)N1C(=CC(C2=C(N=CC(=C12)Cl)OCCOCCOCCOCCO)=O)C RTXJBTFTKDIJGJ-UHFFFAOYSA-N 0.000 claims 1
- HUMITMAJXKZKTO-UHFFFAOYSA-N 3-chloro-2-[8-chloro-5-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethoxy]-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C(=C(C#N)C=CC=1)N1C(=CC(C2=C(N=CC(=C12)Cl)OCCOCCOCCOCCO)=O)C HUMITMAJXKZKTO-UHFFFAOYSA-N 0.000 claims 1
- BKQQXYPCYMAYNN-UHFFFAOYSA-N 3-chloro-2-[8-chloro-5-[2-[2-[2-(2-hydroxyethoxy)ethoxy]ethoxy]ethylamino]-2-methyl-4-oxo-1,6-naphthyridin-1-yl]benzonitrile Chemical compound ClC=1C(=C(C#N)C=CC=1)N1C(=CC(C2=C(N=CC(=C12)Cl)NCCOCCOCCOCCO)=O)C BKQQXYPCYMAYNN-UHFFFAOYSA-N 0.000 claims 1
- TXBPZBKXZMRZAD-UHFFFAOYSA-N 8-chloro-1-(2,6-dichloro-4-fluorophenyl)-5-(2,3-dihydroxypropoxy)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)F)Cl)CO)=O)OCC(CO)O TXBPZBKXZMRZAD-UHFFFAOYSA-N 0.000 claims 1
- MHXJMDYNADZPBS-UHFFFAOYSA-N 8-chloro-1-(2,6-dichloro-4-fluorophenyl)-5-(2-hydroxyethoxy)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)F)Cl)CO)=O)OCCO MHXJMDYNADZPBS-UHFFFAOYSA-N 0.000 claims 1
- NEIITZWACZSJEY-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(difluoromethyl)-5-(2,3-dihydroxypropoxy)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C(F)F)=O)OCC(CO)O NEIITZWACZSJEY-UHFFFAOYSA-N 0.000 claims 1
- FJNDSSQBHOYCSW-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-5-(2-methylsulfonylethylamino)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)NCCS(=O)(=O)C FJNDSSQBHOYCSW-UHFFFAOYSA-N 0.000 claims 1
- FWXGVUPQGGYNPO-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-5-(3-hydroxypropyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CCCO FWXGVUPQGGYNPO-UHFFFAOYSA-N 0.000 claims 1
- OSWNTPIKMGXESA-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-5-(oxetan-3-ylmethoxy)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCC1COC1 OSWNTPIKMGXESA-UHFFFAOYSA-N 0.000 claims 1
- WUOZKIDPSWHTMY-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-5-[2-(2-methoxyethoxy)ethoxy]-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCCOCCOC WUOZKIDPSWHTMY-UHFFFAOYSA-N 0.000 claims 1
- DBYLIOOXAAJUAD-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-5-[[3-(hydroxymethyl)oxetan-3-yl]methoxy]-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCC1(COC1)CO DBYLIOOXAAJUAD-UHFFFAOYSA-N 0.000 claims 1
- YRKPFBCMURMWHH-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-6H-1,6-naphthyridine-4,5-dione Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)O YRKPFBCMURMWHH-UHFFFAOYSA-N 0.000 claims 1
- VXGWLTJUJVHZMV-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-methyl-5-(1,2,4-triazol-1-yl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)N1N=CN=C1 VXGWLTJUJVHZMV-UHFFFAOYSA-N 0.000 claims 1
- BUFKMYQMAHJBHT-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-methyl-5-(1-methyltetrazol-5-yl)oxy-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OC1=NN=NN1C BUFKMYQMAHJBHT-UHFFFAOYSA-N 0.000 claims 1
- SNMWXWMIXVAIPH-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-methyl-5-(2,3,4-trihydroxybutoxy)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(C(CO)O)O SNMWXWMIXVAIPH-UHFFFAOYSA-N 0.000 claims 1
- PPOFRZAMNFVMDG-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-methyl-5-(oxetan-3-ylmethoxy)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC1COC1 PPOFRZAMNFVMDG-UHFFFAOYSA-N 0.000 claims 1
- XUENZROPARGQNH-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-methyl-5-[(1-methyltetrazol-5-yl)amino]-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)NC1=NN=NN1C XUENZROPARGQNH-UHFFFAOYSA-N 0.000 claims 1
- ITPBWSUVZDXXGH-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-methyl-5-[(2-methyltetrazol-5-yl)amino]-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)NC=1N=NN(N=1)C ITPBWSUVZDXXGH-UHFFFAOYSA-N 0.000 claims 1
- XDAYAPJRCGNDON-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(1,2-dihydroxyethyl)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C(CO)O XDAYAPJRCGNDON-UHFFFAOYSA-N 0.000 claims 1
- LHOYPFIGBFSNOS-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(1,2-dihydroxyethyl)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)C(CO)O LHOYPFIGBFSNOS-UHFFFAOYSA-N 0.000 claims 1
- GJDHCQVTACKVML-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(1,3-dihydroxypropan-2-yloxy)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OC(CO)CO GJDHCQVTACKVML-UHFFFAOYSA-N 0.000 claims 1
- ALXTXATYLGFTMA-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxy-3-methylbutoxy)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCC(C(C)(C)O)O ALXTXATYLGFTMA-UHFFFAOYSA-N 0.000 claims 1
- XYYWOQHYDUCWCD-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxy-3-methylbutoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(C(C)(C)O)O XYYWOQHYDUCWCD-UHFFFAOYSA-N 0.000 claims 1
- DDDSGZFENQKDDY-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCC(CO)O DDDSGZFENQKDDY-UHFFFAOYSA-N 0.000 claims 1
- OZAPVCJGIULPCZ-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-2-(methoxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)COC)=O)OCC(CO)O OZAPVCJGIULPCZ-UHFFFAOYSA-N 0.000 claims 1
- XSTIKDBUFTWNNB-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(CO)O XSTIKDBUFTWNNB-UHFFFAOYSA-N 0.000 claims 1
- QGZGTAVFFSLXOZ-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-4-oxo-1,6-naphthyridine-2-carbonitrile Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C#N)=O)OCC(CO)O QGZGTAVFFSLXOZ-UHFFFAOYSA-N 0.000 claims 1
- VCMAAYDSJJLABR-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxymethyl)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)COCC(CO)O VCMAAYDSJJLABR-UHFFFAOYSA-N 0.000 claims 1
- NACUEOVEOGDGII-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropyl)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC(CO)O NACUEOVEOGDGII-UHFFFAOYSA-N 0.000 claims 1
- HCTCNUKJFUGPRV-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropyl)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)CC(CO)O HCTCNUKJFUGPRV-UHFFFAOYSA-N 0.000 claims 1
- WDGVFWSLMYEAGZ-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,4-dihydroxy-3-oxobutan-2-yl)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)C(C)(C(CO)=O)O WDGVFWSLMYEAGZ-UHFFFAOYSA-N 0.000 claims 1
- LBUKDMRMXBBNPX-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2-hydroxy-2-methylpropoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(C)(C)O LBUKDMRMXBBNPX-UHFFFAOYSA-N 0.000 claims 1
- HLIDCCUMHXLIRM-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2-hydroxyacetyl)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)C(CO)=O HLIDCCUMHXLIRM-UHFFFAOYSA-N 0.000 claims 1
- LJRVXPVZQPEPBW-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2-hydroxyethoxy)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCCO LJRVXPVZQPEPBW-UHFFFAOYSA-N 0.000 claims 1
- VJWMFGICJZJHAO-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2-hydroxyethoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCCO VJWMFGICJZJHAO-UHFFFAOYSA-N 0.000 claims 1
- MHWBUIZVNLFKEP-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2-hydroxyethoxyamino)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)NOCCO MHWBUIZVNLFKEP-UHFFFAOYSA-N 0.000 claims 1
- LYJIYGZXENLAPE-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(3,4-dihydroxybutyl)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CCC(CO)O LYJIYGZXENLAPE-UHFFFAOYSA-N 0.000 claims 1
- BSKNWGRELQKJMA-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCC1OC(OC1)(C)C BSKNWGRELQKJMA-UHFFFAOYSA-N 0.000 claims 1
- DDDSGZFENQKDDY-SNVBAGLBSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[(2R)-2,3-dihydroxypropoxy]-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OC[C@@H](CO)O DDDSGZFENQKDDY-SNVBAGLBSA-N 0.000 claims 1
- GMTMPGCBJCCSBJ-NEPJUHHUSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[(2R,4S)-4-hydroxy-2-(hydroxymethyl)pyrrolidin-1-yl]-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)N1[C@H](C[C@@H](C1)O)CO GMTMPGCBJCCSBJ-NEPJUHHUSA-N 0.000 claims 1
- ZFFSQOGPNZWLRZ-GASCZTMLSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[(3S,4R)-3,4-dihydroxypyrrolidin-1-yl]-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)N1C[C@H]([C@H](C1)O)O ZFFSQOGPNZWLRZ-GASCZTMLSA-N 0.000 claims 1
- BMSQSCMJMBTGSK-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[2-(1H-imidazol-5-yl)ethylamino]-2-methyl-1,6-naphthyridin-4-one Chemical compound N1C=NC(=C1)CCNC1=C2C(C=C(N(C2=C(C=N1)Cl)C1=C(C=CC=C1Cl)Cl)C)=O BMSQSCMJMBTGSK-UHFFFAOYSA-N 0.000 claims 1
- IKPDCTPBFIIQRF-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(COCC(CO)O)O IKPDCTPBFIIQRF-UHFFFAOYSA-N 0.000 claims 1
- MGUUTBZGBKDYFF-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[3-hydroxy-2,2-bis(hydroxymethyl)propoxy]-2-methyl-1,7-naphthyridin-4-one Chemical compound CC1=CC(=O)C2=C(OCC(CO)(CO)CO)C=NC(Cl)=C2N1C1=C(Cl)C=CC=C1Cl MGUUTBZGBKDYFF-UHFFFAOYSA-N 0.000 claims 1
- SJJQFMZJSMAXHL-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(CO)(C)CO SJJQFMZJSMAXHL-UHFFFAOYSA-N 0.000 claims 1
- MREYLDDLEGSHRF-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[3-hydroxy-2-(hydroxymethyl)propoxy]-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCC(CO)CO MREYLDDLEGSHRF-UHFFFAOYSA-N 0.000 claims 1
- TUKPJFKLDJTXDD-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[3-hydroxy-2-(hydroxymethyl)propoxy]-2-(methoxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)COC)=O)OCC(CO)CO TUKPJFKLDJTXDD-UHFFFAOYSA-N 0.000 claims 1
- SCIZOVDYSFRBNZ-JTQLQIEISA-N 8-chloro-1-(2,6-dichlorophenyl)-5-[[(2S)-2,3-dihydroxypropyl]amino]-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)NC[C@@H](CO)O SCIZOVDYSFRBNZ-JTQLQIEISA-N 0.000 claims 1
- KWKBWPLUKPGJCR-UHFFFAOYSA-N 8-chloro-1-[2,6-dichloro-4-(3-morpholin-4-ylprop-1-ynyl)phenyl]-5-(2-hydroxyethoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)C#CCN1CCOCC1)Cl)C)=O)OCCO KWKBWPLUKPGJCR-UHFFFAOYSA-N 0.000 claims 1
- SYWRDVNCTMJCFH-UHFFFAOYSA-N 8-chloro-1-[2,6-dichloro-4-[3-(1,1-dioxo-1,4-thiazinan-4-yl)prop-1-ynyl]phenyl]-5-(2-hydroxyethoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)C#CCN1CCS(CC1)(=O)=O)Cl)C)=O)OCCO SYWRDVNCTMJCFH-UHFFFAOYSA-N 0.000 claims 1
- YLYMIVSKYAHRGN-UHFFFAOYSA-N 8-chloro-1-[2,6-dichloro-4-[3-(dimethylamino)prop-1-ynyl]phenyl]-5-[(2,2-dimethyl-1,3-dioxolan-4-yl)methoxy]-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)C#CCN(C)C)Cl)C)=O)OCC1OC(OC1)(C)C YLYMIVSKYAHRGN-UHFFFAOYSA-N 0.000 claims 1
- PGJVAYQMCYJFFH-UHFFFAOYSA-N 8-cyclopropyl-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-2-methyl-1,6-naphthyridin-4-one Chemical compound C1(CC1)C=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCC(CO)O PGJVAYQMCYJFFH-UHFFFAOYSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
- BAKFDWZBSGAYAR-UHFFFAOYSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)F)Cl)C)=O)OCCOCCOCCOCCO Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=C(C=C1Cl)F)Cl)C)=O)OCCOCCOCCOCCO BAKFDWZBSGAYAR-UHFFFAOYSA-N 0.000 claims 1
- XYYWOQHYDUCWCD-HNNXBMFYSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OC[C@@H](C(C)(C)O)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OC[C@@H](C(C)(C)O)O XYYWOQHYDUCWCD-HNNXBMFYSA-N 0.000 claims 1
- XYYWOQHYDUCWCD-OAHLLOKOSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OC[C@H](C(C)(C)O)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OC[C@H](C(C)(C)O)O XYYWOQHYDUCWCD-OAHLLOKOSA-N 0.000 claims 1
- LYJIYGZXENLAPE-NSHDSACASA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC[C@@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC[C@@H](CO)O LYJIYGZXENLAPE-NSHDSACASA-N 0.000 claims 1
- LYJIYGZXENLAPE-LLVKDONJSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC[C@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC[C@H](CO)O LYJIYGZXENLAPE-LLVKDONJSA-N 0.000 claims 1
- NACUEOVEOGDGII-JTQLQIEISA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C[C@@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C[C@@H](CO)O NACUEOVEOGDGII-JTQLQIEISA-N 0.000 claims 1
- NACUEOVEOGDGII-SNVBAGLBSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C[C@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C[C@H](CO)O NACUEOVEOGDGII-SNVBAGLBSA-N 0.000 claims 1
- PCMMBCZCYFFFPN-UHFFFAOYSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCCOCCOCCOCCO Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCCOCCOCCOCCO PCMMBCZCYFFFPN-UHFFFAOYSA-N 0.000 claims 1
- XDAYAPJRCGNDON-CYBMUJFWSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)[C@@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)[C@@H](CO)O XDAYAPJRCGNDON-CYBMUJFWSA-N 0.000 claims 1
- XDAYAPJRCGNDON-ZDUSSCGKSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)[C@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)[C@H](CO)O XDAYAPJRCGNDON-ZDUSSCGKSA-N 0.000 claims 1
- 208000016998 Conn syndrome Diseases 0.000 claims 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- 229940082863 Factor VIIa inhibitor Drugs 0.000 claims 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 claims 1
- 102000012195 Fructose-1,6-bisphosphatases Human genes 0.000 claims 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 claims 1
- 108091007911 GSKs Proteins 0.000 claims 1
- 102000051325 Glucagon Human genes 0.000 claims 1
- 108060003199 Glucagon Proteins 0.000 claims 1
- 102000030595 Glucokinase Human genes 0.000 claims 1
- 108010021582 Glucokinase Proteins 0.000 claims 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 claims 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 claims 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 claims 1
- 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 229940122355 Insulin sensitizer Drugs 0.000 claims 1
- 108010041872 Islet Amyloid Polypeptide Chemical class 0.000 claims 1
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 1
- OUAHAENHSCFBMK-UHFFFAOYSA-N N-[1-(2,6-dichloro-4-cyanophenyl)-2-methyl-4-oxo-1,7-naphthyridin-5-yl]-1H-pyrazole-4-sulfonamide Chemical compound ClC1=C(C(=CC(=C1)C#N)Cl)N1C(=CC(C2=C(C=NC=C12)NS(=O)(=O)C=1C=NNC=1)=O)C OUAHAENHSCFBMK-UHFFFAOYSA-N 0.000 claims 1
- DPUOOLDBTIZYJV-UHFFFAOYSA-N N-[2-[[1-(2,6-dichloro-4-cyanophenyl)-2-methyl-4-oxo-1,7-naphthyridin-5-yl]amino]ethyl]methanesulfonamide Chemical compound ClC1=C(C(=CC(=C1)C#N)Cl)N1C(=CC(C2=C(C=NC=C12)NCCNS(=O)(=O)C)=O)C DPUOOLDBTIZYJV-UHFFFAOYSA-N 0.000 claims 1
- MEDIMLKAXOOFGC-UHFFFAOYSA-N N-[2-[[8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-4-oxo-1,6-naphthyridin-5-yl]oxy]ethyl]methanesulfonamide Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)OCCNS(=O)(=O)C MEDIMLKAXOOFGC-UHFFFAOYSA-N 0.000 claims 1
- YBFIRRLWTMWYQM-UHFFFAOYSA-N N-[2-[[8-chloro-1-(2,6-dichlorophenyl)-2-methyl-4-oxo-1,6-naphthyridin-5-yl]oxy]ethyl]methanesulfonamide Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)OCCNS(=O)(=O)C YBFIRRLWTMWYQM-UHFFFAOYSA-N 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 102000019280 Pancreatic lipases Human genes 0.000 claims 1
- 108050006759 Pancreatic lipases Proteins 0.000 claims 1
- 108091006299 SLC2A2 Proteins 0.000 claims 1
- 206010040639 Sick sinus syndrome Diseases 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 claims 1
- RTZDPYBYXWKQFY-UHFFFAOYSA-N [8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxy)-4-oxo-1,6-naphthyridin-2-yl]methyl dihydrogen phosphate Chemical compound P(=O)(OCC=1N(C2=C(C=NC(=C2C(C=1)=O)OCC(CO)O)Cl)C1=C(C=CC=C1Cl)Cl)(O)O RTZDPYBYXWKQFY-UHFFFAOYSA-N 0.000 claims 1
- 230000009102 absorption Effects 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 229940125669 adenosine diphosphate receptor inhibitor Drugs 0.000 claims 1
- 239000000464 adrenergic agent Substances 0.000 claims 1
- 239000000048 adrenergic agonist Substances 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 claims 1
- 239000002160 alpha blocker Substances 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 239000000883 anti-obesity agent Substances 0.000 claims 1
- 230000002785 anti-thrombosis Effects 0.000 claims 1
- 239000003529 anticholesteremic agent Substances 0.000 claims 1
- 229940127226 anticholesterol agent Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 229940125710 antiobesity agent Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 150000001539 azetidines Chemical group 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 229940096699 bile acid sequestrants Drugs 0.000 claims 1
- 239000000480 calcium channel blocker Substances 0.000 claims 1
- 229940097217 cardiac glycoside Drugs 0.000 claims 1
- 239000002368 cardiac glycoside Substances 0.000 claims 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N diethylenediamine Natural products C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
- 229960004666 glucagon Drugs 0.000 claims 1
- 210000002837 heart atrium Anatomy 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 210000003405 ileum Anatomy 0.000 claims 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims 1
- 239000000859 incretin Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000003228 microsomal effect Effects 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 239000006014 omega-3 oil Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229940116369 pancreatic lipase Drugs 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 150000004885 piperazines Chemical group 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000013846 primary aldosteronism Diseases 0.000 claims 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 150000003235 pyrrolidines Chemical group 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000009103 reabsorption Effects 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 229920005989 resin Polymers 0.000 claims 1
- 239000011347 resin Substances 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 150000008143 steroidal glycosides Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 1
- 230000032258 transport Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (17)
1. Spoj, naznačen time, što je predstavljen formulom II ili formulom III:
[image]
gdje:
R1 je C1-4alkil, -CH2CN, -CN, C1-4alkoksiC1-4alkil, halogen-C1-4alkil, -CH=N-OH, -CH=N-O-C1-4alkil, -CH=N-O-(hidroksiC1-4alkil), hidroksi-C1-4alkil, -CH2OP(O)(OH)2, ili C3-5cikloalkil;
R3 je -ORa; -NHRb; -C(O)NH2; -C(O)[hidroksiC1-4alkil]; heterociklil izborno supstituiran s jednim ili više supstituenata neovisno odabranih iz niza koji sadrži OH i hidroksiC1-4alkil; 5-člani ili 6-člani heteroaril izborno supstituiran s jednim ili više C1-4alkila; ili
R3 je C1-4alkil supstituiran s jednim ili više supstituenata neovisno odabranih iz niza koji sadrži - C(O)[hidroksiC1-4alkil] i -ORc;
Ra je -C1-6alkil supstituiran s jednim ili više supstituenata neovisno odabranih iz niza koji sadrži -ORc, - SO2C1-4alkil, -NHS(O)2C1-4alkil, i heterociklil koji je dalje izborno supstituiran s jednim ili više supstituenata neovisno odabranih iz niza koji sadrži C1-4alkil i hidroksiC1-4alkil; ili
Ra je H, -[CH2-CH2-O]n-H, -[CH2-CH2-O]m-CH3, ili heteroaril izborno supstituiran s jednim ili više C1-4alkila; pri čemu n je 2-6 i m je 1-6;
Rb je -C1-6alkil supstituiran s jednim ili više supstituenata neovisno odabranih iz niza koji sadrži -ORc, - C(O)NH-C1-4alkil, -C(O)NH-(hidroksiC1-4alkil), hidroksiC1-4alkil, 5-člani ili 6-člani heteroaril, heterociklil, -SO2C1-4alkil, i -NHS(O)2C1-4alkil; ili
Rb je -S(O)2heteroaril; ili
Rb je 4-člani do 7-člani heterociklil izborno supstituiran s jednom ili više hidroksi skupina; ili
Rb je H, -ORc; -[CH2-CH2-O]n-H, -[CH2-CH2-O]m-CH3, ili heteroaril izborno supstituiran s jednim ili više C1-4alkila; pri čemu n je 2-6 i m je 1-6;
Rc je H ili hidroksiC1-4alkil;
R2 je H, C1-4alkoksi, halogen-C1-4alkoksi, halogen, C1-4alkil, -S-C1-4alkil, ili -NH-C1-4alkil;
R4 je H, halogen, halogen-C1-4alkil, C1-4alkil, ili C3-5cikloalkil;
R5 je H, halogen, CN, C1-4alkoksi, hidroksi-C1-4alkoksi, C1-4alkoksi-C1-4alkoksi, -CH=NH-O-C1-4alkil, ili -CH=NH-O(hidroksiC1-4alkil); ili
R5 je C2-6alkinil izborno supstituiran sa OH ili NRgRh pri čemu su Rg i Rh neovisno H ili C1-4alkil; ili Rg i Rh zajedno s dušikom na koji su oni vezani, tvore 4-člani do 7-člani heterociklil koji izborno sadrži dodatni heteroatom odabran između O, S, i N, pri čemu heteroatom može biti u svojem oksidiranom obliku; i pri čemu je navedeni heterociklil izborno supstituiran sa C1-4alkilom; i
R6 je halogengen, C1-4 alkil ili CN;
ili njegova farmaceutski prihvatljiva sol.
2. Spoj prema patentnom zahtjevu 1, naznačen time, što R1 je CH3, ciklopropil, -CH2OH, ili -CH=NH-OH;
ili njegova farmaceutski prihvatljiva sol.
3. Spoj prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, što R2 je H ili -NH-CH3;
ili njegova farmaceutski prihvatljiva sol.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, što R4 je H ili halogen.
ili njegova farmaceutski prihvatljiva sol.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time, što R5 je H, F, CN, C2-4alkinil supstituiran s OH, ili tiomorfolin;
ili njegova farmaceutski prihvatljiva sol.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 5, naznačen time, što R6 je Cl ili CN.
ili njegova farmaceutski prihvatljiva sol.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 6, naznačen time, što R3 je hidroksiC1-6alkil, hidroksiC1-6alkoksi, -O-(CH2CH2-O)nH, -O-(CH2CH2-O)mCH3, -NH-(CH2CH2O)nH, -NH-(CH2CH2-O)mCH3, azetidin supstituiran s hidroksilom, pirolidin supstituiran s jednim ili više supstituenata neovisno odabranih iz niza koji sadrži hidroksil i hidroksiC1-4alkil; ili piperazin supstituiran s hidroksiC1-4alkilom;
ili njegova farmaceutski prihvatljiva sol.
8. Spoj prema patentnom zahtjevu 1, s formulom III, naznačen time, što R1 je CH3 ili CH2OH, R2 je H, R3 je -ORa ili -NHRb, R4 je Cl, R5 je H ili F, i R6 je Cl;
ili njegova farmaceutski prihvatljiva sol.
9. Spoj prema patentnom zahtjevu 1, naznačen time, što je odabran iz skupine koja sadrži:
(S)-8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
(R)-8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksi-3-metilbutoksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-2-(hidroksimetil)-5-((3-(hidroksimetil)oksetan-3-il)metoksi)-1,6-naftiridin-4(1H)-on;
N-(2-((8-klor-1-(2,6-diklorfenil)-2-(hidroksimetil)-4-okso-1,4-dihidro-1,6-naftiridin-5-il)oksi)etil)metansulfonamid;
8-klor-1-(2,6-diklorfenil)-5-(2-(2-(2-(2-hidroksietoksi)etoksi)etoksi)etoksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(3-hidroksi-2-(hidroksimetil)propoksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-((1,3-dihidroksipropan-2-il)oksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-2-(hidroksimetil)-5-(oksetan-3-ilmetoksi)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-2-(hidroksimetil)-5-(2-(2-metoksietoksi)etoksi)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2-hidroksietoksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-((2-(2-(2-(2-hidroksietoksi)etoksi)etoksi)etil)amino)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-((14-hidroksi-3,6,9,12-tetraoksatetradecil)oksi)-2-metil-1,6-naftiridin-4(1H)-on;
5-(2,5,8,11,14,17-heksaoksanonadekan-19-iloksi)-8-klor-1-(2,6-diklorfenil)-2-metil-1,6-naftiridin-4(1H)-on;
3-klor-2-(8-klor-5-((2-(2-(2-(2-hidroksietoksi)etoksi)etoksi)etil)amino)-2-metil-4-okso-1,6-naftiridin-1(4H)-il)benzonitril;
3-((8-klor-1-(2,6-diklorfenil)-2-metil-4-okso-1,4-dihidro-1,6-naftiridin-5-il)amino)-2-hidroksi-N-(2-hidroksietil)propanamid;
3,5-diklor-4-(5-(2,3-dihidroksipropoksi)-2-metil-4-okso-1,7-naftiridin-1(4H)-il)benzonitril;
8-klor-1-(2,6-diklorfenil)-5-((17-hidroksi-3,6,9,12,15-pentaoksaheptadecil)oksi)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(3-(2,3-dihidroksipropoksi)-2-hidroksipropoksi)-2-metil-1,6-naftiridin-4(1H)-on;
3-klor-2-(8-klor-5-(2-(2-(2-(2-hidroksietoksi)etoksi)etoksi)etoksi)-2-metil-4-okso-1,6-naftiridin-1(4H)-il)benzonitril;
N-(2-((1-(2,6-diklor-4-cijanofenil)-2-metil-4-okso-1,4-dihidro-1,7-naftiridin-5-il)amino)etil)metansulfonamid;
3-klor-2-(8-klor-5-(2-(2-(2-(2-hidroksietoksi)etoksi)etoksi)etoksi)-2-metil-4-okso-1,6-naftiridin-1(4H)-il)-5-fluorbenzonitril;
8-klor-1-(2,6-diklor-4-fluorfenil)-5-((17-hidroksi-3,6,9,12,15-pentaoksaheptadecil)oksi)-2-metil-1,6-naftiridin-4(1H)-on;
3,5-diklor-4-(8-klor-5-(4-(2-hidroksietil)piperazin-1-il)-2-metil-4-okso-1,6-naftiridin-1(4H)-il)benzonitril;
8-klor-1-(2,6-diklorfenil)-2-metil-5-(2,3,4-trihidroksibutoksi)-1,6-naftiridin-4(1H)-on; 3,5-diklor-4-(5-((2-hidroksietil)amino)-2-metil-4-okso-1,7-naftiridin-1(4H)-il)benzonitril;
8-klor-1-(2,6-diklorfenil)-5-(3-hidroksi-2,2-bis(hidroksimetil)propoksi)-2-metil-1,6-naftiridin-4(1H)-on;
3,5-diklor-4-(5-(3-hidroksiazetidin-1-il)-2-metil-4-okso-1,7-naftiridin-1(4H)-il)benzonitril;
8-klor-1-(2,6-diklorfenil)-5-(2-(2-(2-(2-hidroksietoksi)etoksi)etoksi)etoksi)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-((2R,4S)-4-hidroksi-2-(hidroksimetil)pirolidin-1-il)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklor-4-fluorfenil)-5-(2-(2-(2-(2-hidroksietoksi)etoksi)etoksi)etoksi)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-((3R,4S)-3,4-dihidroksipirolidin-1-il)-2-metil-1,6-naftiridin-4(1H)-on;
3-klor-2-(8-klor-5-(2,3-dihidroksipropoksi)-2-metil-4-okso-1,6-naftiridin-1(4H)-il)benzonitril;
5-((2-(1H-imidazol-4-il)etil)amino)-8-klor-1-(2,6-diklorfenil)-2-metil-1,6-naftiridin-4(1H)-on;
N-(2-((8-klor-1-(2,6-diklorfenil)-2-metil-4-okso-1,4-dihidro-1,6-naftiridin-5-il)oksi)etil)metansulfonamid;
8-klor-1-(2,6-diklorfenil)-5-((2-(2-(2-(2-hidroksietoksi)etoksi)etoksi)etil)amino)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-2-metil-1,6-naftiridin-4(1H)-on; (S)-8-klor-1-(2,6-diklorfenil)-5-((2,3-dihidroksipropil)amino)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksi-3-metilbutoksi)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(3-hidroksi-2-(hidroksimetil)-2-metilpropoksi)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2-hidroksi-2-metilpropoksi)-2-metil-1,6-naftiridin-4(1H)-on;
3,5-diklor-4-(8-klor-5-(((3R,4S)-4-hidroksitetrahidrofuran-3-il)amino)-2-metil-4-okso-1,6-naftiridin-1(4H)-il)benzonitril;
3,5-diklor-4-(8-klor-5-((2-hidroksietoksi)amino)-2-metil-4-okso-1,6-naftiridin-1(4H)-il)benzonitril;
8-klor-1-(2,6-diklorfenil)-2-metil-5-((1-metil-1H-tetrazol-5-il)amino)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-2-metil-5-((1-metil-1H-tetrazol-5-il)oksi)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-2-metil-5-((2-metil-2H-tetrazol-5-il)amino)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2-hidroksietoksi)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-((2-hidroksietoksi)amino)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-2-metil-5-(oksetan-3-ilmetoksi)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-2-(hidroksimetil)-5-((2-(metilsulfonil)etil)amino)-1,6-naftiridin-4(1H)-on;
8-ciklopropil-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(3-hidroksi-2-(hidroksimetil)propoksi)-2-(metoksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-2-(metoksimetil)-1,6-naftiridin-4(1H)-on;
3-klor-2-(8-klor-2-ciklopropil-5-(2,3-dihidroksipropoksi)-4-okso-1,6-naftiridin-1 (4H)-il)benzonitril;
4-(5-((2-(1H-imidazol-4-il)etil)amino)-2-metil-4-okso-1,7-naftiridin-1(4H)-il)-3,5-diklorbenzonitril;
8-klor-1-(2,6-diklorfenil)-5-((2,2-dimetil-1,3-dioksolan-4-il)metoksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
(R)-8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksi-3-metilbutoksi)-2-metil-1,6-naftiridin-4(1H)-on;
(S)-8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksi-3-metilbutoksi)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklor-4-fluorfenil)-5-(2,3-dihidroksipropoksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklor-4-fluorfenil)-5-(2-hidroksietoksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-2-(difluormetil)-5-(2,3-dihidroksipropoksi)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-4-okso-1,4-dihidro-1,6-naftiridin-2-karbonitril;
8-klor-1-(2,6-diklorfenil)-5-hidroksi-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on; 1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-2-metil-7-(metilamino)-1,6-naftiridin-4(1H)-on;
1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-7-etil-2-metil-1,6-naftiridin-4(1H)-on; 1-(2-klor-6-etilfenil)-5-(2,3-dihidroksipropoksi)-7-etil-2-metil-1,6-naftiridin-4(1H)-on;
1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-7-metoksi-2-metil-1,6-naftiridin-4(1H)-on;
1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-8-etil-2-metil-1,6-naftiridin-4(1H)-on;
N-(1-(2,6-diklor-4-cijanofenil)-2-metil-4-okso-1,4-dihidro-1,7-naftiridin-5-il)-1H-pirazol-4-sulfonamid;
8-klor-1-(2,6-diklorfenil)-2-metil-5-(1H-1,2,4-triazol-1-il)-1,6-naftiridin-4(1H)-on;
3,5-diklor-4-(2-metil-4-okso-5-(1H-pirazol-3-il)-1,7-naftiridin-1(4H)-il)benzonitril;
3,5-diklor-4-(2-metil-5-(1-metil-1H-pirazol-4-il)-4-okso-1,7-naftiridin-1(4H)-il)benzonitril;
8-klor-1-(2,6-diklorfenil)-2-(hidroksimetil)-5-(3-hidroksipropil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(3,4-dihidroksibutil)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
(R)-8-klor-1-(2,6-diklorfenil)-5-(3,4-dihidroksibutil)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
(S)-8-klor-1-(2,6-diklorfenil)-5-(3,4-dihidroksibutil)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropil)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
(R)-8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropil)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
(S)-8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropil)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropil)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(1,2-dihidroksietil)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
(R)-8-klor-1-(2,6-diklorfenil)-5-(1,2-dihidroksietil)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
(S)-8-klor-1-(2,6-diklorfenil)-5-(1,2-dihidroksietil)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(1,2-dihidroksietil)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2-hidroksiacetil)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-((2,3-dihidroksipropoksi)metil)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(((1,3-dihidroksipropan-2-il)oksi)metil)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklorfenil)-5-(2,4-dihidroksi-3-oksobutan-2-il)-2-metil-1,6-naftiridin-4(1H)-on;
1-(4-(3-amino-3-metilbut-1-in-1-il)-2,6-diklorfenil)-8-klor-5-(2,3-dihidroksipropoksi)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklor-4-(3-morpholinoprop-1-in-1-il)fenil)-5-(2-hidroksietoksi)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklor-4-(3-(1,1-dioksidotiomorfolino)prop-1-in-1-il)fenil)-5-(2-hidroksietoksi)-2-metil-1,6-naftiridin-4(1H)-on;
8-klor-1-(2,6-diklor-4-(3-(dimetilamino)prop-1-in-1-il)fenil)-5-((2,2-dimetil-1,3-dioksolan-4-il)metoksi)-2-metil-1,6-naftiridin-4(1H)-on; i
(8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-4-okso-1,4-dihidro-1,6-naftiridin-2-il)metil dihidrogen fosfat;
ili njihova farmaceutski prihvatljiva sol.
10. Spoj prema patentnom zahtjevu 9, naznačen time, što je spoj (S)-8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-on,
ili njegova farmaceutski prihvatljiva sol.
11. Spoj prema patentnom zahtjevu 10, pri čemu je spoj kristalni oblik hidrata (S)-8-klor-1-(2,6-diklorfenil)-5-(2,3-dihidroksipropoksi)-2-(hidroksimetil)-1,6-naftiridin-4(1H)-ona, naznačen time, što posjeduje uzorak rendgenske difrakcije praha (XRPD) koji sadrži jedan ili više maksimuma odabranih od 7,0 ± 0,2 °2θ, 14,1 ± 0,2 °2θ, 18,5 ± 0,2 °2θ, 24,7 ± 0,2 °2θ, 26,0 ± 0,2 °2θ i 26,9 ± 0,2 °2θ, kada se mjeri pomoću CuKα zračenja s valnom duljinom od 1,5418 Å i na temperaturi od oko 22°C.
12. Farmaceutski pripravak, naznačen time, što sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od patentnih zahtjeva 1 do 11, ili njegovu farmaceutski prihvatljivu sol, i jedan ili više farmaceutski prihvatljivih nosača.
13. Kombinacija, naznačena time, što sadrži terapeutski učinkovitu količinu spoja prema bilo kojem od patentnih zahtjeva 1 do 11, i jedno ili više terapeutski aktivnih koagensa.
14. Kombinacija prema zahtjevu 13, naznačena time, što su koagensi odabrani iz niza koji čine antiaritmijska sredstva klase I, antiaritmijska sredstva klase II, antiaritmijska sredstva klase III, antiaritmijska sredstva klase IV, antiaritmijska sredstva klase V, srčani glikozidi, drugi lijekovi koji utječu na otpornost atrija; modulatori hemostaze, antitrombotici; inhibitori trombina; inhibitori faktora VIIa; antikoagulansi, inhibitori faktora Xa, direktni inhibitori trombina; antitrombocitna sredstva, inhibitori ciklooksigenaze, inhibitori receptora adenozin difosfata (ADP), inhibitori fosfodiesteraze, glikoprotein IIB/IIA, inhibitori ponovne pohrane adenozina; sredstva protiv dislipidemije, inhibitori HMG-CoA reduktaze, druga sredstva za snižavanje kolesterola; agonisti PPARa; sekvestranti žučne kiseline; inhibitori apsorpcije kolesterola; inhibitori prijenosa proteina kolesteril estera (CETP); inhibitori transportnog sustava žučne kiseline u ileumu (IBAT inhibitori); smole koje vežu žučne kiseline; nikotinska kiselina i njeni analozi; antioksidansi; omega-3 masne kiseline; antihipertenzijska sredstva, antagonisti adrenergičkih receptora, beta blokatori, alfa blokatori, miješani alfa/beta blokatori; agonisti adrenergičkih receptora, alfa-2 agonisti; inhibitori angiotenzin konvertirajućeg enzima (ACE), blokatori kalcijevih kanala; antagonisti receptora angiotenzina II; antagonisti receptora aldosterona; adrenergički lijekovi centralnog djelovanja, centralni alfa agonisti; diuretička sredstva; sredstva protiv pretilosti, inhibitori pankreasne lipaze, modulatori mikrosomalnog prijenosnog proteina (MTP), inhibitori diacil glicerolaciltransferaze (DGAT), antagonisti kanabinoidnih (CBI) receptora; inzulin i inzulinski analozi; sekretagogi inzulina; sredstva koja poboljšavaju djelovanje inkretina, inhibitori dipeptidil peptidaze IV (DPP-4), agonisti glukagonu sličnog peptida-I (GLP-1); sredstva za senzibilizaciju inzulina, agonisti receptora gama (PPARy) aktiviranog proliferatorom peroksisoma, sredstva koja moduliraju ravnotežu glukoze u jetri, inhibitori fruktoza 1,6-bisfosfataze, inhibitori glikogen fosforilaze, inhibitori kinaze glikogen sintaze, aktivatori glukokinaze; sredstva namijenjena smanjenju/usporavanju apsorpcije glukoze iz crijeva, inhibitori alfa-glukozidaze; sredstva koja antagoniziraju djelovanje ili smanjuju izlučivanje glukagona, analozi amilina; sredstva koja sprečavaju ponovnu apsorpciju glukoze u bubrezima, i inhibitori transportera glukoze 2 (SGLT-2) ovisnog o natriju.
15. Spoj prema bilo kojem od patentnih zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen time, što je za uporabu kao lijek.
16. Spoj prema bilo kojem od patentnih zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, naznačen time, što je za uporabu u liječenju ili prevenciji bolesti ili poremećaja koji reagira na inhibiciju GIRK receptora, pri čemu je bolest ili poremećaj odabran od srčane aritmije, fibrilacije atrija, primarnog hiperaldosteronizma, hipertenzije i sindroma bolesnog sinusa.
17. Spoj za uporabu prema patentnom zahtjevu 16, naznačen time, što navedena bolest ili poremećaj jest fibrilacija atrija.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662410930P | 2016-10-21 | 2016-10-21 | |
CN2016102928 | 2016-10-21 | ||
US201662413292P | 2016-10-26 | 2016-10-26 | |
PCT/IB2017/056515 WO2018073788A1 (en) | 2016-10-21 | 2017-10-19 | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
EP17801105.2A EP3529251B1 (en) | 2016-10-21 | 2017-10-19 | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20221516T1 true HRP20221516T1 (hr) | 2023-02-17 |
Family
ID=60409317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20221516TT HRP20221516T1 (hr) | 2016-10-21 | 2017-10-19 | Derivati naftiridinona i njihova uporaba u liječenju aritmije |
Country Status (33)
Country | Link |
---|---|
US (3) | US10266531B2 (hr) |
EP (2) | EP3529251B1 (hr) |
JP (1) | JP7030802B2 (hr) |
KR (1) | KR102540872B1 (hr) |
CN (1) | CN109843887B (hr) |
AU (2) | AU2017344489C1 (hr) |
BR (1) | BR112019007863A2 (hr) |
CA (1) | CA3038624A1 (hr) |
CL (1) | CL2019001023A1 (hr) |
CO (1) | CO2019003894A2 (hr) |
CR (1) | CR20190201A (hr) |
CU (1) | CU24599B1 (hr) |
DO (1) | DOP2019000100A (hr) |
EC (1) | ECSP19026973A (hr) |
ES (1) | ES2934234T3 (hr) |
FI (1) | FI3529251T3 (hr) |
HR (1) | HRP20221516T1 (hr) |
HU (1) | HUE060882T2 (hr) |
IL (1) | IL266128B (hr) |
JO (1) | JOP20190086A1 (hr) |
LT (1) | LT3529251T (hr) |
MX (1) | MX2019004484A (hr) |
PE (1) | PE20190735A1 (hr) |
PH (1) | PH12019500849A1 (hr) |
PL (1) | PL3529251T3 (hr) |
PT (1) | PT3529251T (hr) |
RS (1) | RS63841B1 (hr) |
SA (1) | SA519401614B1 (hr) |
SG (1) | SG11201902529WA (hr) |
SI (1) | SI3529251T1 (hr) |
TW (1) | TWI759343B (hr) |
UY (1) | UY37445A (hr) |
WO (1) | WO2018073788A1 (hr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
SG11202012973RA (en) * | 2018-06-27 | 2021-01-28 | Bristol Myers Squibb Co | Naphthyridinone compounds useful as t cell activators |
WO2022074567A1 (en) | 2020-10-06 | 2022-04-14 | Novartis Ag | Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia |
AR127698A1 (es) * | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1022214A (en) | 1963-01-31 | 1966-03-09 | Sterling Drug Inc | Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation |
IL51092A0 (en) | 1976-12-10 | 1977-02-28 | Abic Ltd | Naphthyridine derivatives and their preparation |
JPS57176958A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | 1-(2',6'-dichlorophenyl)-2-methylthioindole and its preparation |
JPS57176956A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone |
JPS57176959A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | 1-(2',6'-dichlorophenyl)-2,3bis(methylthio) indole and its preparation |
JPS57176957A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone |
US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
US4559332A (en) | 1983-04-13 | 1985-12-17 | Ciba Geigy Corporation | 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof |
US4698341A (en) | 1983-07-30 | 1987-10-06 | Godecke Aktiengesellschaft | Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis |
US4767762A (en) * | 1985-12-23 | 1988-08-30 | Abbott Laboratories | Tricyclic quinoline and naphthyride antibacterials |
US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
AU1625192A (en) | 1991-05-31 | 1992-12-03 | Zeneca Limited | Heterocyclic derivatives |
EP0618803A4 (en) | 1991-12-19 | 1995-03-22 | Southwest Found Biomed Res | POLYPEPTIDE INHIBITING PROTEIN TRANSFER TO CHOLESTERYL ESTERS, ANTIBODIES AGAINST SYNTHETIC POLYPEPTIDE AND ANTI-ATHEROSCLEROSIS PROPHYLACTIC AND THERAPEUTIC TREATMENTS. |
IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
US5910498A (en) | 1994-10-20 | 1999-06-08 | Wakunaga Seiyaku Kabushiki Kaisha | Pyridonecarboxylic acid derivatives or salts thereof and antibacterial agents comprising the same as active ingredient |
WO1997040036A1 (fr) | 1996-04-19 | 1997-10-30 | Wakunaga Pharmaceutical Co., Ltd. | Nouveaux derives de l'acide pyridonocarboxylique ou des sels de cet acide et agents antibacteriens contenant ces substances en tant que composant actif |
DE19616486C5 (de) | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
KR100516379B1 (ko) | 1996-11-28 | 2005-09-26 | 와쿠나가 세이야쿠 가부시키 가이샤 | 신규 피리돈카르복실산 유도체 또는 그의 염 및 이를 유효 성분으로 하는 의약 |
WO1999064400A1 (en) | 1998-06-12 | 1999-12-16 | Vertex Pharmaceuticals Incorporated | INHIBITORS OF p38 |
CA2339484A1 (en) | 1998-08-03 | 2000-02-17 | Robert A. O'brien | Pyridinones for the treatment of sexual dysfunction |
US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US6677341B2 (en) | 1999-09-23 | 2004-01-13 | Pharmacia Corporation | (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
SK14612002A3 (sk) | 2000-04-12 | 2003-05-02 | Novartis Ag | Farmaceutická kompozícia obsahujúca inhibítor aldosterónsyntázy prípadne v kombinácii s antagonistom AT1-receptora a jej použitie |
JP2003040866A (ja) | 2001-07-31 | 2003-02-13 | Nippon Kayaku Co Ltd | N置換インドール誘導体、その製造法及びそれを有効成分とする害虫防除剤 |
PL369567A1 (en) * | 2001-09-26 | 2005-05-02 | Bayer Pharmaceuticals Corporation | 1,6-naphthyridine derivatives as antidiabetics |
WO2003063781A2 (en) | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
EP1513840B1 (en) | 2002-05-31 | 2006-10-04 | Bayer Pharmaceuticals Corporation | Compounds and compositions for the treatment of diabetes and diabetes-related disorders |
PT1537114E (pt) | 2002-08-07 | 2006-12-29 | Novartis Ag | Compostos orgânicos como agentes para o tratamento de doenças mediadas por aldosterona |
PT1565463E (pt) | 2002-11-18 | 2008-09-10 | Novartis Ag | Derivados de imidazo[1,5-a]piridina e métodos para tratar doenças mediadas pela aldosterona |
EP1670795A1 (en) | 2003-09-18 | 2006-06-21 | ALTANA Pharma AG | Pharmacologically active imidazo 4,5-c pyridines |
US7906521B2 (en) | 2003-09-23 | 2011-03-15 | Merck Sharp & Dohme Corp. | Quinazoline potassium channel inhibitors |
PT1732933E (pt) | 2004-03-26 | 2008-10-20 | Lilly Co Eli | Compostos para o tratamento da dislipidémia |
UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
DE102004018198A1 (de) | 2004-04-15 | 2005-11-03 | Merck Patent Gmbh | Sulfonamide |
EP1748986B1 (en) | 2004-05-28 | 2010-12-01 | Novartis AG | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
US7612088B2 (en) | 2004-05-28 | 2009-11-03 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
EP1749005A1 (en) | 2004-05-28 | 2007-02-07 | Speedel Experimenta AG | Tetrahydro-imidazo ¬1,5-a| pyridin derivatives as aldosterone synthase inhibitors |
ES2656017T3 (es) | 2004-06-24 | 2018-02-22 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
AR049711A1 (es) | 2004-07-09 | 2006-08-30 | Speedel Experimenta Ag | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso |
DE102004054215A1 (de) | 2004-11-10 | 2006-05-11 | Merck Patent Gmbh | Pyridopyrimidinonderivate |
TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
AU2006261841B8 (en) | 2005-06-27 | 2012-12-06 | Exelixis Patent Company Llc | Pyrazole based LXR modulators |
GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
EP1783114A1 (en) | 2005-11-03 | 2007-05-09 | Novartis AG | N-(hetero)aryl indole derivatives as pesticides |
EP1956910B1 (en) | 2005-11-23 | 2014-09-17 | The Board of Regents of The University of Texas System | Oncogenic ras-specific cytotoxic compound and methods of use thereof |
AR056888A1 (es) | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
WO2007116908A1 (ja) | 2006-04-04 | 2007-10-18 | Taiyo Nippon Sanso Corporation | メタン分離方法、メタン分離装置及びメタン利用システム |
TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
JP2010501573A (ja) | 2006-08-25 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | アルドステロン合成酵素および/または11−β−ヒドロキシラーゼおよび/またはアロマターゼが介在する疾患の処置のための縮合イミダゾール誘導体 |
RU2009127642A (ru) | 2006-12-18 | 2011-01-27 | Новартис АГ (CH) | 1-замещенные производные имидазола и их применение в качестве ингибиторов альдостеронсинтазы |
US8143278B2 (en) | 2006-12-18 | 2012-03-27 | Novartis Ag | Organic compounds |
AU2007334416A1 (en) | 2006-12-18 | 2008-06-26 | Novartis Ag | Imidazoles as aldosterone synthase inhibitors |
DE602008003015D1 (de) | 2007-03-29 | 2010-11-25 | Novartis Ag | Heterocyclische spiroverbindungen |
JP5355582B2 (ja) | 2008-02-22 | 2013-11-27 | 大塚製薬株式会社 | ベンゾジアゼピン化合物及び医薬組成物 |
WO2010012745A2 (en) | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | Benzimidazoles |
WO2011018611A1 (en) | 2009-08-10 | 2011-02-17 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
GB0917571D0 (en) | 2009-10-07 | 2009-11-25 | Karobio Ab | Novel estrogen receptor ligands |
DK2610255T3 (en) | 2010-08-25 | 2016-05-30 | Neopharm Co Ltd | 1H-benzo [d] imidazol-5-yl compounds and a composition for the treatment of inflammatory diseases |
EP2524915A1 (en) | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
WO2013007676A1 (en) | 2011-07-12 | 2013-01-17 | F. Hoffmann-La Roche Ag | Aminomethyl quinolone compounds |
AU2013203252B2 (en) | 2012-01-27 | 2015-08-20 | Gilead Sciences, Inc. | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
WO2013152063A1 (en) | 2012-04-05 | 2013-10-10 | Boehringer Ingelheim International Gmbh | Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase |
US9067894B1 (en) | 2013-03-07 | 2015-06-30 | Vanderbilt University | Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest |
WO2014152317A2 (en) | 2013-03-15 | 2014-09-25 | Melinta Therapeutics, Inc. | Methods of treating gonorrhea infections using quinolone antibiotics |
US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
AR096022A1 (es) | 2013-04-11 | 2015-12-02 | Basf Se | Compuestos de pirimidinio sustituido, útiles para combatir plagas de animales |
WO2015019347A1 (en) | 2013-08-08 | 2015-02-12 | Yeda Research And Development Company Ltd. | Girk as a therapeutic target of immune disorders and a marker of b cell subtypes |
EP3088399A4 (en) | 2013-12-26 | 2017-10-25 | Kinki University | Alkoxycarbonyl hemiacetal-type ester prodrug of pyridone carboxylic acid antibacterial drug |
CA2958645A1 (en) | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
KR20180016485A (ko) * | 2015-06-09 | 2018-02-14 | 바이엘 파마 악티엔게젤샤프트 | 무스카린성 m2 수용체의 양성 알로스테릭 조정제 |
JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
-
2017
- 2017-06-16 JO JOP/2019/0086A patent/JOP20190086A1/ar unknown
- 2017-10-18 UY UY0001037445A patent/UY37445A/es not_active Application Discontinuation
- 2017-10-19 SG SG11201902529WA patent/SG11201902529WA/en unknown
- 2017-10-19 PT PT178011052T patent/PT3529251T/pt unknown
- 2017-10-19 PE PE2019000829A patent/PE20190735A1/es unknown
- 2017-10-19 TW TW106135836A patent/TWI759343B/zh active
- 2017-10-19 SI SI201731279T patent/SI3529251T1/sl unknown
- 2017-10-19 EP EP17801105.2A patent/EP3529251B1/en active Active
- 2017-10-19 AU AU2017344489A patent/AU2017344489C1/en active Active
- 2017-10-19 CU CU2019000042A patent/CU24599B1/es unknown
- 2017-10-19 US US15/788,248 patent/US10266531B2/en active Active
- 2017-10-19 BR BR112019007863A patent/BR112019007863A2/pt active Search and Examination
- 2017-10-19 ES ES17801105T patent/ES2934234T3/es active Active
- 2017-10-19 JP JP2019520981A patent/JP7030802B2/ja active Active
- 2017-10-19 MX MX2019004484A patent/MX2019004484A/es unknown
- 2017-10-19 CA CA3038624A patent/CA3038624A1/en active Pending
- 2017-10-19 HR HRP20221516TT patent/HRP20221516T1/hr unknown
- 2017-10-19 CN CN201780063857.XA patent/CN109843887B/zh active Active
- 2017-10-19 FI FIEP17801105.2T patent/FI3529251T3/fi active
- 2017-10-19 LT LTEPPCT/IB2017/056515T patent/LT3529251T/lt unknown
- 2017-10-19 PL PL17801105.2T patent/PL3529251T3/pl unknown
- 2017-10-19 WO PCT/IB2017/056515 patent/WO2018073788A1/en unknown
- 2017-10-19 EP EP22195204.7A patent/EP4141006A1/en not_active Withdrawn
- 2017-10-19 HU HUE17801105A patent/HUE060882T2/hu unknown
- 2017-10-19 KR KR1020197014044A patent/KR102540872B1/ko active IP Right Grant
- 2017-10-19 CR CR20190201A patent/CR20190201A/es unknown
- 2017-10-19 RS RS20221152A patent/RS63841B1/sr unknown
-
2019
- 2019-03-01 US US16/290,313 patent/US10844055B2/en active Active
- 2019-04-15 CL CL2019001023A patent/CL2019001023A1/es unknown
- 2019-04-15 EC ECSENADI201926973A patent/ECSP19026973A/es unknown
- 2019-04-16 DO DO2019000100A patent/DOP2019000100A/es unknown
- 2019-04-16 CO CONC2019/0003894A patent/CO2019003894A2/es unknown
- 2019-04-17 PH PH12019500849A patent/PH12019500849A1/en unknown
- 2019-04-18 SA SA519401614A patent/SA519401614B1/ar unknown
- 2019-04-18 IL IL266128A patent/IL266128B/en active IP Right Grant
-
2020
- 2020-06-29 AU AU2020204341A patent/AU2020204341B2/en active Active
- 2020-10-15 US US17/071,311 patent/US11530213B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20221516T1 (hr) | Derivati naftiridinona i njihova uporaba u liječenju aritmije | |
ES2234097T3 (es) | Ftalazinas con actividad inhibidora de la angiogenesis. | |
CN105593224B (zh) | 作为溴结构域抑制剂的新型喹唑啉酮类化合物 | |
TWI579284B (zh) | 咪唑并吡咯啶酮化合物 | |
JP4722851B2 (ja) | キノリンカリウムチャネル阻害剤 | |
KR100782091B1 (ko) | 배변을 촉진하는 의약 조성물 | |
JP4801335B2 (ja) | 抗新生物薬としての2,4,ジ(ヘテロ−)アリールアミノ(−オキシ)−5−置換ピリミジン | |
AU2016323297A1 (en) | Hepatitis B core protein modulators | |
TW201803854A (zh) | 經胺取代之芳基或雜芳基化合物 | |
EA026977B1 (ru) | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b | |
JP2019531326A5 (hr) | ||
CN105189514A (zh) | 作为bet-蛋白抑制剂用于治疗过度增殖性疾病的吡咯并-和吡唑并-***并二氮杂卓 | |
EP1608631A2 (en) | Bi-cyclic pyrimidine inhibitors of tgf beta | |
SI2933252T1 (en) | Kinase inhibitors as apoptotic signal regulators | |
KR20120044966A (ko) | 1,2,4-트리아졸로〔1,5a〕 피리딘 유도체의 제조 및 용도 | |
WO2016102493A1 (en) | Imidazopyridine ezh2 inhibitors | |
MXPA02012943A (es) | Compuestos de cinolina. | |
EP3004088A1 (en) | Slc2a transporter inhibitors | |
TW201718549A (zh) | 做為人類免疫缺陷病毒複製抑制劑之5-(n-苯甲基四氫異喹啉-6-基)吡啶-3-基乙酸衍生物 | |
CN114787144A (zh) | 吡啶酮化合物及用于调节蛋白激酶的方法 | |
RU2450814C2 (ru) | Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза | |
EA025240B1 (ru) | ЗАМЕЩЕННЫЕ 4,5,6,7-ТЕТРАГИДРО-1H-ПИРАЗОЛО[4,3-c]ПИРИДИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННОГО СРЕДСТВА И ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ, СОДЕРЖАЩИЕ ИХ | |
US7579344B2 (en) | Pyrimidine derivatives possessing cell-cycle inhibitors activity | |
EP3310355A1 (en) | Inhibitors of ptp4a3 for the treatment of cancer | |
KR20200104336A (ko) | 수용체 티로신 키나제 억제제의 Tyro3, Axl 및 Mertk (TAM) 패밀리로서의 헤테로고리 화합물 |